Application of quinolin compound in treating thyroid cancer
Patent Information
- Application Number
- CN202380081748.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-12-01
- Filing Date
- 2023-11-30
- Publication Date
- 2025-07-11
AI Technical Summary
Existing treatments for differentiated thyroid cancer have limited effects on iodine-refractory patients, especially those whose disease has progressed after tyrosine kinase inhibitors and VEGFR-targeted therapy, and lack effective follow-up treatment options.
Using N-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-3-fluoro Phenyl)-N-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide (compound of formula (I) or a pharmaceutically acceptable salt thereof, as a single agent or in combination, is used for the treatment of differentiated thyroid cancer by inhibiting the activity of multiple tyrosine kinases, especially those refractory to iodine Sexually differentiated thyroid cancer.
The compound shows good anti-tumor activity, has a significant inhibitory effect on differentiated thyroid cancer cells, and has shown good efficacy and safety in clinical trials, improving the therapeutic effect of iodine-refractory differentiated thyroid cancer. .
Smart Images
Figure CN120302974A_ABST